Adaptimmune Therapeutics PLC
ADAPY· OTC
Filed Feb 27, 2019 · 10-K · 58 days after period end · 0001558370-19-001209
derived · Computed from the longer spans the company filed.
| Metric | Q4 2018dderived from reported figures | Q4 2017dderived from reported figures | Q4 2016dderived from reported figures |
|---|---|---|---|
| Revenue | $1.48M | $4.27M | $8.54M |
| Net Income | -$36.17M | -$27.26M | -$15.41M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
ended Dec 31, 2018 · filed Feb 27, 2019 · 58 d after period end